Study guide
4.3 Antipsychotics, Neuroleptic Malignant Syndrome, and Lithium Neurotoxicity
Certified Specialist in Poison Information CSPI
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Pharmacology & Toxicology Principles
1.1 Toxicokinetics: Absorption, Distribution, Metabolism, and Elimination Alterations in Overdose 1.2 Toxicodynamics, Receptor Pharmacology, and Dose-Response Relationships 1.3 Cellular and Biochemical Mechanisms of Toxicity 1.4 Hepatic Biotransformation, Phase I/II Reactions, and CYP450 Interactions
2 Chapter 2: Poison Center Case Assessment Fundamentals
2.1 Exposure History: The Questions That Change Management 2.2 Toxicologic Calculations: Doses, Concentrations, and Conversions
3 Chapter 3: Analgesics, Opioids & Over-the-Counter Medications
3.1 Acetaminophen Overdose: Pathophysiology, Rumack-Matthew Nomogram, and NAC Protocols 3.2 Salicylates: Pathophysiology, Acid-Base Derangements, and Urinary Alkalinization 3.3 Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Miscellaneous OTC Analgesics 3.4 Opioids, Opioid Toxidrome, and Naloxone Titration 3.5 Cough and Cold Products, Antihistamines, Muscle Relaxants, and Local Anesthetics
4 Chapter 4: Psychotropic & Neurologic Medications
4.1 Tricyclic and Cyclic Antidepressants: Cardiotoxicity, ECG Findings, and Bicarbonate Therapy 4.2 SSRIs, SNRIs, Novel Antidepressants, and Serotonin Syndrome 4.3 Antipsychotics, Neuroleptic Malignant Syndrome, and Lithium Neurotoxicity 4.4 Benzodiazepines, Z-drugs, Barbiturates, and Major Anticonvulsants
5 Chapter 5: Cardiovascular Drugs & Substances of Abuse
5.1 Beta-Blockers, Calcium Channel Blockers, and High-Dose Insulin Euglycemia Therapy 5.2 Digoxin and Cardiac Glycosides: Mechanism, Arrhythmias, and Digoxin Immune Fab 5.3 Sympathomimetics, Cocaine, Amphetamines, Synthetic Cannabinoids, and Hallucinogens 5.4 Caffeine, Theophylline, and Over-the-Counter Stimulants 5.5 Cannabis, GHB, Nitrites, and Nicotine Products
6 Chapter 6: Endocrine, Antimicrobial & Miscellaneous Medications
6.1 Antidiabetic Agents, Metformin Lactic Acidosis, and Thyroid Hormone 6.2 Antimicrobials, Vitamins and Minerals, and Veterinary Products
7 Chapter 7: Household, Chemical & Inhalational Toxins
7.1 Caustic and Corrosive Ingestions: Acids vs. Alkalis, Tissue Necrosis, and Endoscopic Grading 7.2 Cleaning Products, Personal Care Products, and Household Chemicals 7.3 Hydrocarbons and Halogenated Solvents: Aspiration Risks and Myocardial Sensitization 7.4 Carbon Monoxide, Cyanide, Hydrogen Sulfide, and Inhalational Irritants
8 Chapter 8: Pesticides, Heavy Metals & Toxic Alcohols
8.1 Organophosphates, Carbamates, Pyrethroids, and Cholinesterase Antidotes 8.2 Rodenticides, Herbicides, Repellents, and Other Pesticides 8.3 Ethylene Glycol, Methanol, and Isopropanol: Metabolism, Osmolal Gaps, and Fomepizole 8.4 Lead, Mercury, Arsenic, Iron Toxicity, and Chelation Protocols
9 Chapter 9: Toxic Plants, Mushrooms & Foodborne Toxins
9.1 Toxic Plants: Cardiac Glycosides, Anticholinergics, Nicotinics, and Sodium Channel Activators 9.2 Oxalate, Irritant, Hallucinogenic, and Stimulant Plants 9.3 Mushroom Poisoning: Amatoxins, Monomethylhydrazine, Muscarine, and Coprine 9.4 Scombroid, Ciguatera, Tetrodotoxin, Paralytic Shellfish, and Botulism 9.5 Bacterial Foodborne Illness and Food Poisoning Triage
10 Chapter 10: Envenomations & Bites
10.1 North American Pit Vipers (Crotalinae): Envenomation Assessment and Antivenom Management 10.2 Elapid Snakebites (Coral Snakes): Neurotoxicity, Clinical Course, and Antivenin 10.3 Black Widow, Brown Recluse Spiders, and Bark Scorpion Stings 10.4 Hymenoptera Stings, Ticks, and Other Arthropods 10.5 Marine Envenomations: Jellyfish, Stingrays, Catfish, and Lionfish
11 Chapter 11: Clinical Assessment, Toxidromes & Triage
11.1 Recognition of Classic Toxidromes and Vital Sign Pattern Analysis 11.2 Severity Assessment, Exposure Urgency, and Poison Center Telephone Triage Flow 11.3 Home Observation vs. Emergency Department Referral Decision-Making 11.4 Diagnostic Toxicology: Acid-Base Analysis, Gaps, ECG Intervals, and Drug Testing
12 Chapter 12: Decontamination, Antidotes & Elimination
12.1 Gastrointestinal Decontamination: Activated Charcoal, Whole Bowel Irrigation, and Contraindications 12.2 Essential Poison Center Antidotes: Indications, Mechanisms, and Titration Pearls 12.3 Enhanced Elimination: Urinary Alkalinization, MDAC, Hemodialysis, and Hemoperfusion 12.4 Resuscitation and Supportive Care: Seizures, Hyperthermia, and Hemodynamic Shock
13 Chapter 13: Pediatric Poisoning & High-Risk Hazards
13.1 Pediatric "One-Pill-Can-Kill" Agents and Pediatric Toxic Dose Thresholds 13.2 Button Batteries, Rare-Earth Magnets, and Expandable Foreign Bodies 13.3 Developmental Ingestion Patterns, Liquid Detergent Pods, and Essential Oils
14 Chapter 14: Communication, NPDS Documentation & Prevention
14.1 Emergency Call Communication, Panicked Callers, and Healthcare Provider Consultations 14.2 National Poison Data System (NPDS) Coding Standards and Medical Outcome Categorization 14.3 Scheduled Follow-up Protocols, Medical Toxicologist Consultation Triggers, and Public Health Surveillance 14.4 Evidence-Based Poison Prevention, PPPA Regulations, and Community Outreach
4.3 Antipsychotics, Neuroleptic Malignant Syndrome, and Lithium Neurotoxicity
Key Takeaways Explain This Topic AI
Antipsychotic toxicity spans first-generation agents (potent D2 antagonism, severe extrapyramidal symptoms, and chlorpromazine alpha-1 blockade) and second-generation agents (5-HT2A/D2 antagonism, quetiapine bezoar/sedation, clozapine agranulocytosis/ileus, and olanzapine miosis).
Acute dystonic reactions stem from acute dopamine-acetylcholine imbalance in the nigrostriatal pathway; first-line rescue is IV/IM diphenhydramine or benztropine, followed by 48 to 72 hours of oral therapy to prevent recurrence.
Neuroleptic Malignant Syndrome (NMS) presents with the classic tetrad of generalized 'lead-pipe' rigidity, hyporeflexia, severe hyperthermia, and autonomic instability with massive CK elevation; management centers on neuroleptic cessation, cooling, and dopaminergic pharmacotherapy (bromocriptine, amantadine) or dantrolene.
Lithium is handled identically to sodium in the renal proximal tubule (80% reabsorbed); volume depletion, dehydration, NSAIDs, thiazide diuretics, and ACE inhibitors diminish GFR and trigger compensatory proximal reabsorption, precipitating toxicity.
EXTRIP recommends extracorporeal treatment for lithium > 4.0 mEq/L with impaired kidney function, or for decreased consciousness, seizures, or life-threatening dysrhythmias at any level, and suggests it for levels > 5.0 mEq/L or significant confusion; rebound requires serial levels over 12 hours.
Last updated: September 2026
Antipsychotics and lithium carbonate represent two core pillars of psychiatric pharmacotherapy for schizophrenia, bipolar disorder, and major affective illnesses. In overdose and toxic accumulation states, these medications trigger severe neurological, cardiovascular, and metabolic decompensation. A comprehensive mastery of dopamine-receptor pharmacology, the distinction between acute extrapyramidal syndromes and Neuroleptic Malignant Syndrome (NMS), and the unique renal handling of lithium is fundamental for specialist practice in poison information.
Antipsychotic Pharmacology: Typical vs. Atypical Classes
Antipsychotics are divided into first-generation (typical) and second-generation (atypical) classes, differing markedly in their receptor binding profiles and overdose manifestations.
1. First-Generation (Typical) Antipsychotics
First-generation antipsychotics—including high-potency agents ( haloperidol , fluphenazine ) and low-potency agents ( chlorpromazine , thioridazine )—function primarily as competitive antagonists at central dopamine D2 receptors :
High-Potency Agents (Haloperidol, Fluphenazine): Minimal anticholinergic or alpha-adrenergic activity; overdose produces intense central D2 blockade resulting in parkinsonism, acute dystonic reactions, akathisia, and obtundation, with relatively preserved blood pressure.
Low-Potency Agents (Chlorpromazine, Thioridazine): Possess potent antagonist properties at vascular alpha-1 adrenergic receptors, muscarinic acetylcholine receptors, and cardiac ion channels. Chlorpromazine overdose causes marked orthostatic hypotension, reflex tachycardia, sedation, and miosis. Thioridazine exerts potent myocardial fast sodium channel blockade and IKr potassium channel blockade, leading to wide-complex ventricular dysrhythmias and Torsades de Pointes.
2. Second-Generation (Atypical) Antipsychotics
Second-generation agents combine 5-HT2A receptor antagonism with variable D2 receptor antagonism, along with diverse affinities for histaminic, muscarinic, and adrenergic targets:
Quetiapine: Potent H1 and alpha-1 antagonist with weak D2 affinity. Overdose characteristically causes marked somnolence, coma, and profound sinus tachycardia (from reflex response to alpha-1 vasodilation). Quetiapine tablets can aggregate into large pharmacobezoars in the stomach, resulting in erratic, delayed peak absorption and protracted coma lasting multiple days.
Olanzapine: Structurally related to clozapine; exhibits high affinity for H1, alpha-1, 5-HT2A, and muscarinic receptors. Overdose frequently manifests with pinpoint pupils (miosis) and central nervous system depression, closely mimicking an opioid toxidrome , but without response to naloxone.
Clozapine: Highly toxic in overdose; causes severe sedation, central anticholinergic delirium, seizures (dose-dependent), marked orthostatic hypotension, and paradoxical sialorrhea (hypersalivation) driven by muscarinic M4 agonism and alpha-2 blockade. Clozapine also causes profound gastrointestinal hypomotility, leading to fatal anticholinergic ileus and bowel necrosis. Idiosyncratic reactions include life-threatening agranulocytosis and myocarditis.
Ziprasidone: Moderate D2/5-HT2A antagonist; causes dose-dependent QTc interval prolongation, requiring continuous cardiac telemetry.
Aripiprazole: Partial D2 and 5-HT1A receptor agonist; exhibits a favorable therapeutic index with mild somnolence and tremor in overdose, though pediatric accidental exposures can provoke paradoxical agitation and dystonia.
Extrapyramidal Symptoms (EPS) and Acute Dystonia Management
Extrapyramidal symptoms arise from an acute perturbation of the balance between dopaminergic and cholinergic neurotransmission in the nigrostriatal pathway :
Acute Dystonic Reactions
Acute dystonia is an involuntary, painful spasmodic contraction of discrete muscle groups occurring within hours to days of initiating or escalating D2 antagonist therapy:
Clinical Manifestations: Spasmodic torticollis (neck twisting), oculogyric crisis (sustained upward deviation of the eyes), trismus (jaw clenching), grimacing, glossal protrusion, opisthotonos (arching of the spine), and potentially fatal laryngeal dystonia (stridor and airway compromise).
Pharmacological Antidote: Parenteral anticholinergic administration restores the dopamine-acetylcholine equilibrium:
Diphenhydramine: 25 to 50 mg IV or IM in adults (1 mg/kg in pediatrics).
Benztropine: 1 to 2 mg IV or IM in adults.
Onset and Maintenance Mandate: Dramatic clinical relief typically occurs within 10 to 20 minutes of intravenous injection. Because typical antipsychotics have elimination half-lives exceeding 24 to 48 hours (much longer than diphenhydramine's 4- to 6-hour half-life), oral anticholinergic therapy must be continued for 48 to 72 hours (e.g., diphenhydramine 25–50 mg PO TID or benztropine 1–2 mg PO BID) to prevent recurrent dystonic storm.
Other Extrapyramidal Syndromes
Akathisia: Subjective motor restlessness and compulsive pacing. Treated with centrally acting beta-blockers ( propranolol 10–20 mg PO TID) or low-dose benzodiazepines.
Parkinsonism: Bradykinesia, resting tremor, and cogwheel rigidity developing over days to weeks. Managed by reducing the neuroleptic dose or adding oral benztropine.
Tardive Dyskinesia: Involuntary, choreiform movements of the tongue, face, and extremities resulting from chronic dopamine receptor up-regulation; does not respond to anticholinergics and is treated with VMAT2 inhibitors (e.g., deutetrabenazine, valbenazine).
- Neuroleptic Malignant Syndrome (NMS)
- Pathophysiology and Precipitants
Neuroleptic Malignant Syndrome is a life-threatening, idiosyncratic reaction triggered by profound central dopamine D2 receptor blockade within the hypothalamus and basal ganglia. Hypothalamic dopamine antagonism disrupts the preoptic anterior thermoregulatory set-point and impairs peripheral heat dissipation, while striatal dopamine antagonism provokes massive, uninhibited skeletal muscle contraction.
Precipitants include any D2 antagonist (haloperidol, fluphenazine, chlorpromazine, olanzapine, risperidone, quetiapine), antiemetics with D2 blocking properties (metoclopramide, prochlorperazine, promethazine), and critically, the abrupt withdrawal of dopamine agonists (levodopa, carbidopa, bromocriptine, amantadine) in patients with Parkinson's disease.
Clinical Presentation and Diagnostic Tetrad
Severe Generalized Rigidity: Described as "lead-pipe" rigidity (uniform resistance throughout the entire range of passive motion) or "cogwheel" rigidity. Deep tendon reflexes are characteristically hyporeflexic or normal , in stark contrast to the hyperreflexia and clonus of Serotonin Syndrome.
Hyperthermia: Core body temperatures characteristically exceed 38.5°C to 40.5°C (101°F to 105°F) , driven by continuous muscular rigidity and hypothalamic failure.
Autonomic Instability: Marked blood pressure lability (fluctuating hypertension and hypotension), severe sinus tachycardia, profuse diaphoresis, tachypnea, and cardiac dysrhythmias.
Altered Mental Status: Evolves from initial confusion and catatonic mutism to stupor, agitated delirium, and deep coma.
Laboratory Hallmarks
Marked Creatine Kinase (CK) Elevation: Ranging from >1,000 IU/L in mild cases to >50,000 to 100,000 IU/L in fulminant cases, reflecting widespread rhabdomyolysis.
Leukocytosis: White blood cell count characteristically elevated to 10,000 to 40,000/mm³ with a left shift.
Metabolic Derangements: Hyperkalemia, hyperphosphatemia, hyperuricemia, and elevated serum creatinine from myoglobinuric acute kidney injury.
Stepwise Management of NMS
Discontinue Causative Agents: Stop all neuroleptics immediately. If caused by dopamine agonist withdrawal, immediately restart the dopaminergic agent.
Supportive Resuscitation and Cooling: Vigorous IV crystalloid hydration (targeting urine output >= 2 mL/kg/hr to flush myoglobin and protect renal tubules) combined with aggressive external cooling.
Dopaminergic Agonist Pharmacotherapy:
Bromocriptine: Direct central D2 receptor agonist. Administer 2.5 to 5 mg orally or via NG tube every 8 hours , titrating as needed (commonly to a maximum of about 40 mg/day) until rigidity and hyperthermia abate.
Amantadine: Facilitates dopamine release and blocks reuptake. Administer 100 mg orally or via NG tube every 12 hours , up to 400 mg/day.
Direct Muscle Relaxant — Dantrolene:
Mechanism: Ryanodine receptor (RyR1) antagonist that blocks calcium release from the sarcoplasmic reticulum of skeletal muscle, uncoupling excitation-contraction and terminating muscular thermogenesis.
Dosing: Administer 1 to 2.5 mg/kg IV bolus , repeated every 5 to 10 minutes as needed up to a maximum cumulative dose of 10 mg/kg/day .
Lithium Neurotoxicity and Toxicokinetics
Lithium is a small monovalent cation (atomic weight about 7; lithium carbonate is about 74 g/mol). It has no plasma protein binding and distributes into total body water with an apparent volume of distribution of 0.7 to 0.9 L/kg.
Renal Handling and Drug Interactions
Lithium is eliminated almost exclusively by renal excretion. It is freely filtered at the glomerulus, after which 80% of the filtered load is reabsorbed in the proximal convoluted tubule , handled identically to sodium. The kidney cannot distinguish lithium from sodium. Any physiological state or medication that depletes total body sodium or decreases glomerular filtration rate prompts compensatory proximal tubular sodium reabsorption, simultaneously driving lithium reabsorption and triggering severe toxicity:
Precipitating Medication / Condition Mechanism of Renal Impairment Impact on Serum Lithium Concentration
Thiazide Diuretics (e.g., HCTZ, Chlorthalidone) Inhibit Na+/Cl- cotransporter in distal tubule -> natriuresis -> volume contraction -> compensatory massive proximal Na+/Li+ reabsorption Increases serum lithium levels by 25% to 50% within 3 to 7 days
NSAIDs (e.g., Ibuprofen, Naproxen) Inhibit renal prostaglandin E2 synthesis -> renal vasoconstriction -> reduced GFR and increased tubular reabsorption Increases serum lithium levels by 15% to 40% (aspirin has minimal effect)
ACE Inhibitors / ARBs (e.g., Lisinopril, Losartan) Dilate efferent renal arterioles -> decrease intraglomerular hydrostatic pressure -> acute reduction in GFR Increases serum lithium levels significantly; often causes delayed, profound toxicity
Dehydration, Salt Restriction, Diarrhea, Vomiting Extracellular fluid volume contraction -> activation of renin-angiotensin-aldosterone system -> maximal proximal reabsorption Precipitates severe chronic lithium toxicity
Classification of Exposure Patterns
Acute Overdose (Lithium-Naive): Ingestion of a large single dose. Serum concentrations rise rapidly, but lithium distributes slowly across the blood-brain barrier. Patients exhibit prominent early gastrointestinal symptoms (nausea, vomiting, profuse diarrhea), while central nervous system toxicity is delayed by 24 to 48 hours. Serum concentrations correlate poorly with early clinical severity.
Acute-on-Chronic Overdose: A patient on long-term lithium ingests an acute overdose. Because tissue and brain stores are already partially or fully saturated, acute elevations in serum levels rapidly translate into severe neurotoxicity alongside GI distress.
Chronic Toxicity (Accumulation): The most lethal form of lithium poisoning. Develops insidiously over days to weeks secondary to dehydration, intercurrent illness, or newly added medications (NSAIDs, ACE inhibitors, thiazides). Brain tissue concentrations are maximally elevated; patients present with predominantly neurological toxicity , while gastrointestinal symptoms are frequently absent.
Clinical Manifestations of Lithium Toxicity
Neurological Hallmarks: Coarse resting and intention tremors, hyperreflexia, ankle clonus, severe cerebellar ataxia, dysarthria, nystagmus, choreoathetosis, fasciculations, confusion, delirium, seizures, and non-convulsive status epilepticus.
Cardiovascular Effects: Sinus node dysfunction, PR prolongation, T-wave flattening or inversion, and rare conduction blocks.
Endocrine and Renal Sequelae: Nephrogenic diabetes insipidus (NDI) from down-regulation of aquaporin-2 channels in the collecting ducts, leading to polyuria, polydipsia, and hypernatremia; chronic tubulointerstitial nephritis.
SILENT Syndrome: Syndrome of Irreversible Lithium-Effectuated Neurotoxicity —persistent, permanent cerebellar dysfunction, dementia, extrapyramidal signs, and brainstem encephalopathy persisting for greater than 2 months following complete lithium cessation and normalization of serum levels.
Elimination Strategies and Extracorporeal Treatment (EXTRIP)
Decontamination: Activated charcoal does not bind lithium due to its small ionic radius. Whole Bowel Irrigation (WBI) with polyethylene glycol electrolyte solution (PEG-ELS at 1.5–2 L/hr in adults) is reserved for massive acute ingestions of sustained-release lithium tablets presented within 2 to 4 hours.
Intravenous Fluid Resuscitation: Administer 0.9% Normal Saline (200–300 mL/hr) to restore intravascular volume, establish euvolemia, and provide sodium ions to suppress compensatory proximal tubular lithium reabsorption. Forced diuresis or sodium bicarbonate diuresis is ineffective and causes fluid overload.
Indications for Extracorporeal Treatment (EXTRIP Workgroup, lithium):
Recommended: impaired kidney function with serum lithium > 4.0 mEq/L ; OR a decreased level of consciousness, seizures, or life-threatening dysrhythmias at any lithium concentration .
Suggested: serum lithium > 5.0 mEq/L ; significant confusion ; or an expected time of more than 36 hours to reach a lithium concentration below 1.0 mEq/L with optimal management.
EXTRIP does not use separate acute and chronic numeric cutoffs; the chronic pattern matters because brain lithium is already high, so neurologic signs appear at lower serum levels. Intermittent hemodialysis is the preferred modality.
Post-Hemodialysis Rebound: Lithium follows a two-compartment kinetic model. Hemodialysis rapidly clears the intravascular compartment, but intracellular lithium redistributes slowly back into plasma over the subsequent 6 to 12 hours. Serial lithium concentrations must be followed over the 12 hours after dialysis (EXTRIP) ; repeat hemodialysis or continuous renal replacement therapy (CRRT) is indicated if serum concentrations rebound above toxic thresholds.